Mostrando ítems 1-6 de 6
Pérez Garay, Marta (Fecha de defensa: 2011-02-07)
Este trabajo demuestra que los genes que codifican para los enzimas beta-galactosido alfa-2,3-sialiltransferasa 3 (ST3Gal III), y en menor medida beta-galactosido alfa-2,3-sialiltransferasa 4 (ST3Gal ...
Guerrero Barrado, Pedro Enrique (Fecha de defensa: 2020-07-29)
Pancreatic Ductal Adenocarcinoma (PDA), the most common pancreatic cancer, remains one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard ...
Sarrats Carbó, Ariadna (Fecha de defensa: 2011-02-10)
Els pacients amb càncer presenten una taxa de supervivència superior si es diagnostiquen a estadis inicials, per la qual cosa és indispensable disposar de marcadors tumorals adequats. Glicoformes de ...
Ferri Iglesias, María José (Fecha de defensa: 2012-09-27)
Serum levels of several molecules associated to pancreatic adenocarcinoma (PDAC) pathophysiology are evaluated in this work, in order to determine their diagnostic value, distinguishing between PDAC ...
Balmaña Esteban, Meritxell (Fecha de defensa: 2016-07-07)
Cancer is one of the leading causes of death worldwide. Pancreatic ductal adenocarcinoma (PDAC) is characterized by high intrinsic aggressiveness and late diagnosis, causing poor prognosis and resulting ...
Miró Domènech, Laura (Fecha de defensa: 2023-01-13)
Pancreatic ductal adenocarcinoma (PDA) presents a dismal prognosis mainly due to its delayed diagnosis, its aggressiveness, and resistance to existing therapies. Aberrant glycosylation and, in particular, ...